Significance of HBV DNA levels at 12 weeks of telbivudine treatment and the 3 years treatment outcome

Journal of Hepatology

Volumn 55, Issue 3, 2011, Pages 522-528

  Seto, Wai Kay ^a   Lai, Ching Lung ^a   Fung, James ^a   Wong, Danny Ka Ho ^a   Yuen, John Chi Hang ^a   Hung, Ivan Fan Ngai ^a   Yuen, Man Fung ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Chronic hepatitis B; Resistance; Viral suppression; Week 12; Week 24

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B(E) ANTIGEN; TELBIVUDINE; VIRUS DNA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; DISEASE DURATION; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEROCONVERSION; TREATMENT DURATION; TREATMENT OUTCOME; VIROLOGY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; MUTATION; NUCLEOSIDES; PREDICTIVE VALUE OF TESTS; PYRIMIDINONES; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84860390069     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2010.11.018     Document Type: Article

References (32)

1. C.L. Lai, and M.F. Yuen Chronic hepatitis B - new goals, new treatment N Engl J Med 359 2008 2488 2491
2. M.F. Yuen Revisiting the natural history of chronic hepatitis B: impact of new concepts on clinical management J Gastroenterol Hepatol 22 2007 973 976
3. C.J. Chen, H.I. Yang, J. Su, C.L. Jen, S.L. You, and S.N. Lu Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level JAMA 295 2006 65 73 (Pubitemid 43042691)
4. M.F. Yuen, W.K. Seto, D.H. Chow, K. Tsui, D.K. Wong, and V.W. Ngai Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease Antivir Ther 12 2007 1295 1303
5. Y.F. Liaw, J.J. Sung, W.C. Chow, G. Farrell, C.Z. Lee, and H. Yuen Lamivudine for patients with chronic hepatitis B and advanced liver disease N Engl J Med 351 2004 1521 1531
6. C.L. Lai, E. Gane, Y.F. Liaw, C.W. Hsu, S. Thongsawat, and Y. Wang Telbivudine versus lamivudine in patients with chronic hepatitis B N Engl J Med 357 2007 2576 2588 (Pubitemid 350294224)
7. Y.F. Liaw, E. Gane, N. Leung, S. Zeuzem, Y. Wang, and C.L. Lai 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B Gastroenterology 136 2009 486 495
8. J. Hou, Y.K. Yin, D. Xu, D. Tan, J. Niu, and X. Zhou Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: results at 1 year of a randomized, double-blind trial Hepatology 47 2008 447 454 (Pubitemid 351280712)
9. H.L. Chan, E.J. Heathcote, P. Marcellin, C.L. Lai, M. Cho, and Y.M. Moon Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial Ann Intern Med 147 2007 745 754 (Pubitemid 351664439)
10. S. Zeuzem, E. Gane, Y.F. Liaw, S.G. Lim, A. DiBisceglie, and M. Buti Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B J Hepatol 51 2009 11 20
11. M.F. Yuen, E. Sablon, C.K. Hui, H.J. Yuan, H. Decraemer, and C.L. Lai Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy Hepatology 34 2001 785 791 (Pubitemid 32928004)
12. M. Seifer, A. Patty, I. Serra, B. Li, and D.N. Standring Telbivudine, a nucleoside analog inhibitor of HBV polymerase, has a different in vitro cross-resistance profile than the nucleotide analog inhibitors adefovir and tenofovir Antiviral Res 81 2009 147 155
13. D.J. Tenney, R.E. Rose, C.J. Baldick, K.A. Pokornowski, B.J. Eggers, and J. Fang Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy Hepatology 49 2009 1503 1514
14. A. Snow-Lampart, B.J. Chappell, M. Curtis, Y. Zhu, E.J. Heathcote, and P. Marcellin Week 96 resistance surveillance for HBeAg positive and negative subjects with chronic HBV infection randomized to receive tenofovir df 300mg qd [abstract] Hepatology 48 2008 745A
15. L. European Association For The Study Of The EASL Clinical Practice Guidelines: management of chronic hepatitis B J Hepatol 50 2009 227 242
16. A.S. Lok, and B.J. McMahon Chronic hepatitis B: update 2009 Hepatology 50 2009 661 662
17. S. Locarnini, A. Hatzakis, J. Heathcote, E.B. Keeffe, T.J. Liang, and D. Mutimer Management of antiviral resistance in patients with chronic hepatitis B Antivir Ther 9 2004 679 693 (Pubitemid 39434331)
18. E.B. Keeffe, S. Zeuzem, R.S. Koff, D.T. Dieterich, R. Esteban-Mur, and E.J. Gane Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B Clin Gastroenterol Hepatol 5 2007 890 897 (Pubitemid 47127032)
19. J.M. Pawlotsky, G. Dusheiko, A. Hatzakis, D. Lau, G. Lau, and T.J. Liang Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach Gastroenterology 134 2008 405 415 (Pubitemid 351181309)
20. M.F. Yuen, J. Fung, W.K. Seto, D.K. Wong, J.C. Yuen, and C.L. Lai Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy Antivir Ther 14 2009 679 685
21. H.G. Hass, T. Bock, O. Nehls, and S. Kaiser Rapid HBV DNA decrease (week 12) is an important prognostic factor for first-line treatment with adefovir dipivoxil for chronic hepatitis B J Gastroenterol 44 2009 871 877
22. H.G. Niesters, F. Zoulim, C. Pichoud, M. Buti, F. Shapiro, and N. D'Heuvaert Validation of the INNO-LiPA HBV DR assay [version 2] in monitoring hepatitis B virus-infected patients receiving nucleoside analog treatment Antimicrob Agents Chemother 54 2010 1283 1289
23. S.W. Aberle, J. Kletzmayr, B. Watschinger, B. Schmied, N. Vetter, and E. Puchhammer-Stockl Comparison of sequence analysis and the INNO-LiPA HBV DR line probe assay for detection of lamivudine-resistant hepatitis B virus strains in patients under various clinical conditions J Clin Microbiol 39 2001 1972 1974 (Pubitemid 32417056)
24. E. Sablon, and F. Shapiro Advances in molecular diagnosis of HBV infection and drug resistance Int J Med Sci 2 2005 8 16 (Pubitemid 40935437)
25. C.W. Hsu, Y.C. Chen, Y.F. Liaw, E. Gane, M. Manns, and S. Zeuzem Prolonged efficacy and safety of 3 years of continuous telbivudine treatment in pooled data from GLOBE and 015 studies in chronic hepatitis B patients (Abstract) J Hepatol 50 2009 S331
26. J.D. Jia, E. Gane, Y.M. Wang, S. Thongsawat, H. Ren, and Y.C. Chen Hepatol Int 4 2010 56
27. Innogenetics. INNO-LIPA HBV DR v2. Innogenetics Group; 2007. p. 22-23.
28. S. Carrouee-Durantel, D. Durantel, B. Werle-Lapostolle, C. Pichoud, L. Naesens, and J. Neyts Suboptimal response to adefovir dipivoxil therapy for chronic hepatitis B in nucleoside-naive patients is not due to pre-existing drug-resistant mutants Antivir Ther 13 2008 381 388 (Pubitemid 352016731)
29. M.F. Yuen, D.Y. Fong, D.K. Wong, J.C. Yuen, J. Fung, and C.L. Lai Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response Hepatology 46 2007 1695 1703
30. Y.Y. Lui, K.K. Tsoi, V.W. Wong, J.H. Kao, J.L. Hou, and E.K. Teo Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as the rescue therapy Antivir Ther 15 2010 145 155
31. R.D. Fleischer, and A.S.F. Lok Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B J Hepatol 51 2009 787 791
32. D.Y. But, M.F. Yuen, J. Fung, and C.L. Lai Safety evaluation of telbivudine Expert Opin Drug Saf 9 2010 821 829